DEFJ Moves to Convert Preferred Stock, Eyeing 9.99% Stake in Transcode Therapeutics
RNAZ has more than doubled off its 52-week low of $3.82 on light trading volume (0.1× avg).
Summary
DEFJ, an affiliate of CK Life Sciences, has filed an irrevocable notice to convert preferred stock into 216,755 common shares, aiming for a 9.99% stake in Transcode Therapeutics, contingent on stockholder approval of key proposals.
Key Events · Ownership and Investor Activity · RNAZ
-
DEFJ Files Irrevocable Conversion Notice
DEFJ, an affiliate of CK Life Sciences, submitted an irrevocable notice to convert 21.6755 shares of Series B Preferred Stock into 216,755 common shares, contingent on stockholder approval of Proposals 1 and 2 at the upcoming annual meeting.
-
Targets 9.99% Ownership Stake
Post-conversion, DEFJ will hold approximately 9.99% of the outstanding common stock, up from its current 8.8% stake, signaling strong investor confidence.
-
Contingent on Stockholder Approval
The conversion is contingent on approval of Proposals 1 and 2, which are part of the company's plan to regain Nasdaq compliance and address its going concern warning.
-
Potential Dilution for Existing Shareholders
The conversion will increase the outstanding share count, potentially diluting existing shareholders, but it also strengthens the company's balance sheet by reducing preferred stock overhang.
Analysis · RNAZ · Life Sciences
An affiliate of CK Life Sciences, DEFJ, has delivered an irrevocable notice to convert 21.6755 shares of Series B Preferred Stock into 216,755 common shares, a move that hinges on stockholder approval of Proposals 1 and 2 at the upcoming annual meeting. If approved, DEFJ's ownership would climb to approximately 9.99% of the outstanding common stock, marking a notable vote of confidence from a major investor as the company works to regain Nasdaq compliance and resolve its going concern warning. While the conversion is part of a broader effort to strengthen the balance sheet, it also raises the specter of dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.4% of the 1723 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNAZ was trading at $8.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $3.82 to $20.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.